

## ORAL CANCER: KEY FACTS AND FIGURES

### WORLDWIDE ORAL CANCER FACTS

- There are over 600,000 new cases of head and neck cancer each year worldwide.<sup>1</sup>
- The prevalence of oral cancer is relatively higher in men, in older people, and among people of low education and low income.<sup>2</sup>
- There are three primary pathways by which most people develop oral cancer: tobacco use, alcohol consumption, and exposure to HPV-16.<sup>3</sup>

### U.S. ORAL CANCER FACTS

- In the U.S., more than 48,000 individuals will be diagnosed with oral or pharyngeal cancer this year, with close to 9,600 deaths resulting from this disease.<sup>4</sup>
- In the U.S. oral cancer kills one person per hour, 24 hours per day.<sup>5</sup>

### ORAL CANCER OUTCOMES

- More than 40% of those diagnosed with oral cancer die within five years due to these cases being discovered as a late-stage malignancy.<sup>6</sup>
- Early diagnosis can more than double a patient's chances of survival. When detected early, oral cancer patients have a remarkably improved 80% to 90% survival rate.<sup>7</sup>
- In addition to the health benefits for screening, early detection and intervention could represent a potential 80% in costs savings versus detection and intervention of a later staged oral cancer.<sup>8</sup>
- When caught at a late stage, the physical and psychological impact of oral cancer can be severe. Surgical removal may require reconstruction of portions of the oral cavity or face. There may also be therapy required to assist with speech, eating food and adapting to a new way of life. In addition, the fabrication and use of dental and/or facial prostheses may be required.<sup>9</sup>

### ABOUT VIGILANT BIOSCIENCES, INC.

Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert™ Oral Cancer and OncAlert™ Labs product lines include point-of-care and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The OncAlert™ LAB Test and the OncAlert™ RAPID Test are CE Marked and available for sale in certain international markets. The OncAlert™ RAPID Test and OncAlert™ LAB Test are not yet available for sale in the U.S. OraMark™ is a laboratory developed test and is available through OncAlert™ Labs, a CLIA certified laboratory. For more information, visit [www.vigilantbiosciences.com](http://www.vigilantbiosciences.com) and [www.oncalertlabs.com](http://www.oncalertlabs.com).

<sup>1,2</sup> World Health Organization; <sup>3,4,5,7,9</sup> Oral Cancer Foundation; <sup>6</sup> Oral Cancer Awareness Foundation; <sup>8</sup> National Institutes of Health